| 1 |
Liu J, Yu F, Liu Z, Wang X, Li J. A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer. Cancer Biother Radiopharm 2022;37:963-75. [PMID: 34551265 DOI: 10.1089/cbr.2021.0171] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 2 |
Cai Z, Zhou F. A novel Anoikis and immune-related genes marked prognostic signature for colorectal cancer. Medicine (Baltimore) 2022;101:e31127. [PMID: 36401385 DOI: 10.1097/MD.0000000000031127] [Reference Citation Analysis]
|
| 3 |
Li X, Huo X, Zhao C, Chen Z, Xu Z, Yu J, Sun X. A novel chromatin regulator signature predicts the prognosis, clinical features and immunotherapy of colon cancer. Epigenomics 2022;14:1325-41. [PMID: 36545887 DOI: 10.2217/epi-2022-0266] [Reference Citation Analysis]
|
| 4 |
Lin Y, Xiao Y, Liu S, Hong L, Shao L, Wu J. Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer. BMC Med Genomics 2022;15:221. [PMID: 36280825 DOI: 10.1186/s12920-022-01369-8] [Reference Citation Analysis]
|
| 5 |
Huang Y, Zhou J, Zhong H, Xie N, Zhang F, Zhang Z. Identification of a novel lipid metabolism-related gene signature for predicting colorectal cancer survival. Front Genet 2022;13:989327. [DOI: 10.3389/fgene.2022.989327] [Reference Citation Analysis]
|
| 6 |
Liu Y, Chen L, Meng X, Ye S, Ma L. Identification of Hub Genes in Colorectal Adenocarcinoma by Integrated Bioinformatics. Front Cell Dev Biol 2022;10:897568. [DOI: 10.3389/fcell.2022.897568] [Reference Citation Analysis]
|
| 7 |
Xiong K, Tao Z, Zhang Z, Wang J, Zhang P. Identification and Validation of a Prognostic Immune-Related Gene Signature in Esophageal Squamous Cell Carcinoma. Front Bioeng Biotechnol 2022;10:850669. [DOI: 10.3389/fbioe.2022.850669] [Reference Citation Analysis]
|
| 8 |
Guo T, Wang Z, Liu Y. Establishment and verification of a prognostic tumor microenvironment-based and immune-related gene signature in colon cancer. J Gastrointest Oncol 2021;12:2172-91. [PMID: 34790383 DOI: 10.21037/jgo-21-522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Subtil B, Cambi A, Tauriello DVF, de Vries IJM. The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer. Front Immunol 2021;12:724883. [PMID: 34691029 DOI: 10.3389/fimmu.2021.724883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:751407. [PMID: 34659255 DOI: 10.3389/fimmu.2021.751407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 11 |
Li X, Xie M, Yin S, Xiong Z, Mao C, Zhang F, Chen H, Jin L, Lan P, Lian L. Identification and Validation of a Six Immune-Related Genes Signature for Predicting Prognosis in Patients With Stage II Colorectal Cancer. Front Genet 2021;12:666003. [PMID: 34017356 DOI: 10.3389/fgene.2021.666003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
